Ionis Pharmaceuticals received FDA approval for Dawnzera (donidalorsen), a prophylactic therapy for hereditary angioedema (HAE), marking the company's second recent approval for the rare disease. The drug features an autoinjector with dosing intervals optimized for patient convenience. Meanwhile, Sarepta Therapeutics announced refinancing of approximately $700 million of convertible senior notes to strengthen its capital structure amidst ongoing challenges with its Duchenne gene therapy program. Additionally, QuidelOrtho completed $3.4 billion in debt refinancing transactions to improve financial flexibility, underscoring ongoing corporate financial maneuvers within the biotech sector.